Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Net Cash Flow (2019 - 2023)

Alx Oncology Holdings' Net Cash Flow history spans 5 years, with the latest figure at $2.8 million for Q4 2023.

  • For Q4 2023, Net Cash Flow rose 1316.38% year-over-year to $2.8 million; the TTM value through Dec 2023 reached -$26.4 million, up 91.61%, while the annual FY2025 figure was -$1.2 million, 75.33% up from the prior year.
  • Net Cash Flow for Q4 2023 was $2.8 million at Alx Oncology Holdings, up from -$18.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $174.7 million in Q4 2020 and bottomed at -$204.5 million in Q1 2022.
  • The 5-year median for Net Cash Flow is -$5.6 million (2020), against an average of $743555.6.
  • The largest annual shift saw Net Cash Flow skyrocketed 5509.47% in 2020 before it plummeted 4586.41% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at $3.1 million in 2019, then surged by 5509.47% to $174.7 million in 2020, then plummeted by 112.29% to -$21.5 million in 2021, then soared by 98.92% to -$232000.0 in 2022, then skyrocketed by 1316.38% to $2.8 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Net Cash Flow are $2.8 million (Q4 2023), -$18.5 million (Q3 2023), and -$25.2 million (Q2 2023).